Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 603

1.
2.

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A.

Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13.

PMID:
16203934
3.
4.

Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.

Pichichero M, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, Casey J, Gilmet G.

Pediatr Infect Dis J. 2006 Nov;25(11):995-1000.

PMID:
17072120
5.

Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.

Lagos R, Papa T, Muñoz A, Ryall R, Pina M, Bassily E.

Hum Vaccin. 2005 Nov-Dec;1(6):228-31. Epub 2005 Nov 7.

PMID:
17012878
6.

Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.

El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, Balfour G, Booy R.

Vaccine. 2006 Mar 24;24(14):2544-9. Epub 2005 Dec 27.

PMID:
16417952
7.
8.
9.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
10.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
11.

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.

PMID:
19116603
12.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

14.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

15.
16.

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.

Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM.

Vaccine. 2010 Jan 8;28(3):657-63. doi: 10.1016/j.vaccine.2009.10.104. Epub 2009 Nov 4.

PMID:
19895922
17.

Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger.

Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, Bybel M, Carlone G, Briantais P, Ivanoff B, Xerri B, Chippaux JP.

Pediatr Infect Dis J. 2000 Feb;19(2):144-50.

PMID:
10694002
18.

Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.

Findlow H, Southern J, Mabey L, Balmer P, Heyderman RS, Auckland C, Morris R, Miller E, Borrow R.

Clin Vaccine Immunol. 2006 Apr;13(4):507-10.

19.

Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.

Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels MB.

J Infect Dis. 2002 Dec 15;186(12):1848-51. Epub 2002 Nov 14.

20.

Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.

Keyserling HL, Pollard AJ, DeTora LM, Gilmet GP.

Expert Rev Vaccines. 2006 Aug;5(4):445-59. Review.

PMID:
16989625
Items per page

Supplemental Content

Write to the Help Desk